A phase I/II study of a tetanus vaccine booster to prime the immune system prior to administration of a therapeutic vaccine in patients with lethal Glioblastoma multiforme (GBM) brain tumours

Trial Profile

A phase I/II study of a tetanus vaccine booster to prime the immune system prior to administration of a therapeutic vaccine in patients with lethal Glioblastoma multiforme (GBM) brain tumours

Completed
Phase of Trial: Phase I/II

Latest Information Update: 10 Apr 2015

At a glance

  • Drugs PEPIDH1M (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Apr 2015 New trial record
    • 12 Mar 2015 Pooled results from this and one other study (see CTP 700255631) were published in an Annias Immunotherapeutics Media Release.
    • 12 Mar 2015 According to an Annias Immunotherapeutics media release, data from this study were presented in Nature.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top